Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: Our experience and meta-analysis

Journal of Urology

Volumn 188, Issue 3, 2012, Pages 786-791

  Mass, Alon Y ^a   Agalliu, Ilir ^b   Laze, Juliana ^a   Lepor, Herbert ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

hydroxymethylglutaryl CoA reductase inhibitors; neoplasm recurrence local; prostate; prostatic neoplasms; risk

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOCHEMICAL RECURRENCE; BODY MASS; CANCER STAGING; DEMOGRAPHY; DIABETES MELLITUS; FOLLOW UP; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; META ANALYSIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE FREE SURVIVAL; RECURRENT DISEASE; SURVIVAL RATE; SYSTEMATIC REVIEW;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84864917742     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.05.011     Document Type: Article

References (25)

1. C. Baigent, A. Keech, P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 366 2005 1267
2. D.R. Browning, R.M. Martin Statins and risk of cancer: a systematic review and meta-analysis Int J Cancer 120 2007 833
3. E.D. Flick, L.A. Habel, K.A. Chan Statin use and risk of prostate cancer in the California Men's Health Study cohort Cancer Epidemiol Biomarkers Prev 11 2007 2218
4. I. Agalliu, C.A. Salinas, P.D. Hansten Statin use and risk of prostate cancer: results from a population-based epidemiologic study Am J Epidemiol 168 2008 250
5. S. Loeb, D. Kan, B.T. Helfand Is statin use associated with prostate cancer aggressiveness? BJU Int 105 2010 1222
6. E.A. Platz, M.F. Leitzmann, K. Visvanathan Statin drugs and risk of advanced prostate cancer J Natl Cancer Inst 98 2006 1819
7. M.S. Cyrus-David, A. Weinberg, T. Thompson The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report J Urol 173 2005 1923
8. A.M. Mondul, E. Selvin, A.M. De Marzo Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004 Cancer Causes Control 21 2010 671
9. T.J. Murtola, T.L. Tammela, L. Määttänen Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial Int J Cancer 127 2010 1650
10. S. Bonovas, K. Filioussi, N.M. Sitaras Statin use and the risk of prostate cancer: a meta-analysis of 6 randomized clinical trials and 13 observational studies Int J Cancer 123 2008 899
11. S. Loeb, Z. Feng, A. Ross Can we stop prostate specific antigen testing 10 years after radical prostatectomy? J Urol 186 2011 500
12. J.H. Ku, C.W. Jeong, Y.H. Park Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients Prostate Cancer Prostatic Dis 14 2011 63
13. R.J. Hamilton, L.L. Banez, W.J. Aronson Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database Cancer 116 2010 3389
14. L.S. Krane, S.A. Kaul, H.J. Stricker Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen J Urol 183 2010 118
15. C.R. Ritch, G. Hruby, K.K. Badani Effect of statin use on prostatectomy BJU Int 108 2011 E211
16. A.M. Mondul, M. Han, E.B. Humphreys EA: Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery J Urol 185 2011 1268
17. A.V. D'Amico, R. Whittington, S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969
18. D.W. Hosmer, S. Lemeshow Applied Survival Analysis: Regression Modeling to Time to Event Data 1999 John Wiley & Sons New York
19. D.R. Cox Regression models with life-tables (with discussion) J Roy Statist Soc Series B 34 1972 187
20. M.R. Goldstein, L. Mascitelli Effect of statin use on biochemical outcome following radical prostatectomy BJU Int 108 2011 E6
21. S. Sharad, A. Srivastava, S. Ravulapalli Prostate cancer gene expression signature of patients with high body mass index Prostate Cancer Prostatic Dis 14 2011 22
22. E. Rijo Mora, J.A. Lorente Garin, O. BielsaGalí [The impact of statins use in clinically localized prostate cancer treated with radical prostatectomy] Actas Urol Esp 33 2009 351
23. M.A. Moyad, G.S. Merrick, W.M. Butler Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer Urology 66 2005 1150
24. M.S. Katz, P.R. Carroll, J.E. Cowan Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE BJU Int 106 2010 627
25. Health, United States, 2010 With Special Feature on Death and Dying 2011 National Center for Health Statistics Hyattsville